Clinical trial entrants include projects from Gyala, Beijing Biotech and Neowise.
ApexOnco Front Page
Recent articles
Pivotal trials of sonrotoclax plus the group’s BTK degrader are set to start soon.
Three private biotechs enter clinical trials, one targeting KRAS.
But PFS data are lacking, and there are questions about first and second-line plans.
But the company still has a lot to prove with ERAS-0015.
Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.
Early Ibtrozi sales and a low-cost licensing deal with Eisai disappoint investors.
Readout of the Pivot-006 trial is brought forward by nearly a year.
